# NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

> **NCT04270461** · PHASE1 · WITHDRAWN · sponsor: **Jiujiang University Affiliated Hospital**

## Conditions studied

- Hepatocellular Carcinoma
- Glioblastoma
- Medulloblastoma
- Colon Cancer

## Interventions

- **BIOLOGICAL:** NKG2D-based CAR T-cells

## Key facts

- **NCT ID:** NCT04270461
- **Lead sponsor:** Jiujiang University Affiliated Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-17
- **Primary completion:** 2020-10-17
- **Final completion:** 2020-10-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is withdrawn because of administrative reasons
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04270461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04270461, "NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04270461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*